Helicobacter pylori and nonmalignant diseases

Helicobacter

Volumn 8, Issue SUPPL. 1, 2003, Pages 36-43

  Isakov, Vassili A ^a   Malfertheiner, Peter ^b  

^a M F VLADIMIRSKY MOSCOW REGIONAL RESEARCH CLINICAL INSTITUTE   (Russian Federation)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Gastro esophageal reflux disease; Non steroidal anti inflammatory drug related peptic ulcer; Nonulcer dyspepsia; Peptic ulcer disease; Unvestigated dyspepsia

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR;

COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DUODENUM ULCER; DYSPEPSIA; ENDOSCOPY; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; INCIDENCE; NONHUMAN; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; ULCER PERFORATION;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 0142089713     PISSN: 10834389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5378.2003.00169.x     Document Type: Review

References (40)

1. Rosenstock S, Jorgensen T, Bonnevie O, Andersen L. Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults. Gut 2003;52:186-93.
2. Bobrzynski A, Beben P, Budzynski A, et al. Incidence of complications of peptic ulcers in patients with Helicobacter pylori (Hp) infection and/or NSAID use in the era of Hp eradication. Med Sci Monit 2002;8:CR554-7.
3. Gisbert JP, Pajares JM. Review article. Helicobacter pylori infection and gastric outlet obstruction - prevalence of the infection and role of antimicrobial treatment. Aliment Pharmacol Ther 2002;16:1203-8.
4. Chen MH, Wu MS, Lee WC, Wang HP, Lin JT. A multiple logistic regression analysis of risk factors in different subtypes of gastric ulcer. Hepatogastroenterology 2002;49:589-92.
5. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
6. Tomita T, Fukuda Y, Tamura K et al. Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease. Aliment Pharmacol Ther 2002;16:204-9.
7. Forrest EH, MacKenzie JF, Stuart RC, Morris AJ. Helicobacter pylori eradication for peptic ulceration: an observational study in a Scottish primary care setting. Scott Med J 2002;47:28-33.
8. Khan Z, Nair P, O'Shea C, et al. Does Helicobacter pylori eradication reduce the long-term requirements for acid suppressants in patients with a history of peptic ulcer disease in general practice? Results from a four-year longitudinal study. Scand J Gastroenterol 2002;37:144-7.
9. 2 receptor antagonists. Economic and symptomatic benefits. A large prospective study in primary care. Helicobacter 2002;7:91-8.
10. Olafsson S, Hatlebakk JG, Berstad A. Patients with endoscopic gastritis and/or duodenitis improve markedly following eradication of Helicobacter pylori, although less so than patients with ulcers. Scand J Gastroenterol 2002;37:1386-94.
11. Lai KC, Lau CS, Ip WY, et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003;17:799-805.
12. Labenz J, Blum AL, Bolten WW, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002;51:329-35.
13. Campbell DR, Haber MM, Sheldon E, et al. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine. Am J Gastroenterol 2002;97:2208-14.
14. Hawkey CJ, Wilson I, Naesdal J, et al. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut 2002;51:344-50.
15. Calvet X, Gratacos J, Font J, et al. Helicobacter pylori does not play a part in the dyspeptic complaints of rheumatology patients receiving long term treatment with non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2002;61:641-3.
16. Bannwarth B, Dorval E, Caekaert A, Barthelemy P. Influence of Helicobacter pylori eradication therapy on the occurrence of gastrointestinal events in patients treated with conventional non-steroidal antiinflammatory drugs combined with omeprazole. J Rheumatol 2002;29:1975-80.
17. Matsukawa Y, Aoki M, Nishinarita S, et al. Prevalence of Helicobacter pylori in NSAID users with gastric ulcer. Rheumatology (Oxford) 2003.
18. Okan A, Tankurt E, Aslan BU, et al. Relationship between non-steroidal anti-inflammatory drug use and Helicobacter pylori infection in bleeding or uncomplicated peptic ulcers: a case-control study. J Gastroenterol Hepatol 2003;18:18-25.
19. Laheij RJ, Van Rossum LG, Verbeek AL, Jansen JB. Helicobacter pylori infection treatment of non-ulcer dyspepsia: an analysis of meta-analyses. J Clin Gastroenterol 2003;36:315-20.
20. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003 CD002096.
21. Heikkinen M, Farkkila M. Long-term outcome of functional dyspepsia: effect of Helicobacter pylori infection. A 6- to 7-year follow-up study. Scand J Gastroenterol 2002;37:905-10.
22. Hsu PI, Lai KH, Lo GH, et al. Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow up study of 209 patients. Gut 2002;51:15-20.
23. McNamara D, Buckley M, Gilvarry J, O'Morain C. Does Helicobacter pylori eradication affect symptoms in nonulcer dyspepsia: a 5-year follow-up study. Helicobacter 2002;7:317-21.
24. Bolling-Sternevald E, Lauritsen K, Aalykke C, et al. Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 2002;37:1395-402.
25. Koelz HR, Arnold R, Stolte M, Fischer M, Blum AL. Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: a double blind randomised trial with a six month follow up. Gut 2003;52:40-6.
26. Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 2003;326:737.
27. Manes G, Pieramico O, Uomo G, et al. Relationship of sliding hiatus hernia to gastroesophageal reflux disease: a possible role for Helicobacter pylori infection? Dig Dis Sci 2003;48:303-7.
28. Jang TJ, Kim NI, Suh JI, Yang CH. Reflux esophagitis facilitates low Helicobacter pylori infection rate and gastric inflammation. J Gastroenterol Hepatol 2002;17:839-43.
29. McNamara D, Buckley M, O'Morain C. Helicobacter pylori-induced duodenal ulcer frequently coincides with gastro-oesophageal reflux disease. Dig Liver Dis 2002;34:542-6.
30. Malfertheiner P, Dent J, Zeijlon L, et al. Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease - results from a randomized trial programme. Aliment Pharmacol Ther 2002;16:1431-42.
31. Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002;97:2992-7.
32. Miwa H, Sugiyama Y, Ohkusa T, et al. Improvement of reflux symptoms 3 years after cure of Helicobacter pylori infection: a case-controlled study in the Japanese population. Helicobacter 2002;7:219-24.
33. Jang TJ, Kim NI, Yang CH. Carditis is associated with Helicobacter pylori-induced gastritis and not reflux esophagitis. J Clin Gastroenterol 2003;36:26-9.
34. McNamara D, Buckley M, Crotty P, et al. Carditis: all Helicobacter pylori or is there a role for gastro-oesophageal reflux? Scand J Gastroenterol 2002;37:772-7.
35. Oksanen A, Sipponen P, Karttunen R, Rautelin H. Inflammation and intestinal metaplasia at the squamocolumnar junction in young patients with or without Helicobacter pylori infection. Gut 2003;52:194-8.
36. Delaney B, Moayyedi P, Forman D. Initial management strategies for dyspepsia (Cochrane Review). Cochrane Database Syst Rev 2003 CD001961.
37. Chiba N, Van Zanten SJ, Sinclair P, et al. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002;324:1012-6.
38. McColl KE, Murray LS, Gillen D, et al. Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H. pylori testing alone in the management of dyspepsia. BMJ 2002;324:999-1002.
39. Manes G, Menchise A, De Nucci C, Balzano A. Empirical prescribing for dyspepsia. randomised controlled trial of test and treat versus omeprazole treatment. BMJ 2003;326:1118.
40. Wu JC, Chan FK, Ching JY, et al. Empirical treatment based on 'typical' reflux symptoms is inappropriate in a population with a high prevalence of Helicobacter pylori infection. Gastrointest Endosc 2002;55:461-5.